
Alessandra Rossi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3104359/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Overview on gastroretentive drug delivery systems for improving drug bioavailability. International Journal of Pharmaceutics, 2016, 510, 144-158.	5.2	194
2	Opportunity and challenges of nasal powders: Drug formulation and delivery. European Journal of Pharmaceutical Sciences, 2018, 113, 2-17.	4.0	83
3	Characterization of a polyurethane-based controlled release system for local delivery of chlorhexidine diacetate. European Journal of Pharmaceutics and Biopharmaceutics, 2010, 74, 255-264.	4.3	67
4	Particles and powders: Tools of innovation for non-invasive drug administration. Journal of Controlled Release, 2012, 161, 693-702.	9.9	59
5	Lecithin/chitosan controlled release nanopreparations of tamoxifen citrate: Loading, enzyme-trigger release and cell uptake. Journal of Controlled Release, 2013, 167, 276-283.	9.9	55
6	Hesperidin Gastroresistant Microparticles by Spray-Drying: Preparation, Characterization, and Dissolution Profiles. AAPS PharmSciTech, 2009, 10, 391-401.	3.3	51
7	Spray-dried amikacin sulphate powder for inhalation in cystic fibrosis patients: The role of ethanol in particle formation. European Journal of Pharmaceutics and Biopharmaceutics, 2015, 93, 165-172.	4.3	46
8	Dry powder inhalers: An overview of the in vitro dissolution methodologies and their correlation with the biopharmaceutical aspects of the drug products. European Journal of Pharmaceutical Sciences, 2018, 113, 18-28.	4.0	46
9	The application of Quality by Design framework in the pharmaceutical development of dry powder inhalers. European Journal of Pharmaceutical Sciences, 2018, 113, 64-76.	4.0	45
10	Spray dried amikacin powder for inhalation in cystic fibrosis patients: A quality by design approach for product construction. International Journal of Pharmaceutics, 2014, 471, 507-515.	5.2	44
11	"Pierce and inhale―design in capsule based dry powder inhalers: Effect of capsule piercing and motion on aerodynamic performance of drugs. International Journal of Pharmaceutics, 2015, 487, 197-204.	5.2	38
12	Primary Microparticles and Agglomerates of Morphine for Nasal Insufflation. Journal of Pharmaceutical Sciences, 2006, 95, 2553-2561.	3.3	35
13	Pure insulin highly respirable powders for inhalation. European Journal of Pharmaceutical Sciences, 2014, 51, 110-117.	4.0	30
14	Glycyrrhizic Acid and Its Hydrolyzed Metabolite 18Î ² -Glycyrrhetinic Acid as Specific Ligands for Targeting Nanosystems in the Treatment of Liver Cancer. Pharmaceutics, 2021, 13, 1792.	4.5	28
15	In Vivo Assessment of Clobetasol Propionate-Loaded Lecithin-Chitosan Nanoparticles for Skin Delivery. International Journal of Molecular Sciences, 2017, 18, 32.	4.1	27
16	Dose administration maneuvers and patient care in tobramycin dry powder inhalation therapy. International Journal of Pharmaceutics, 2018, 548, 182-191.	5.2	27
17	Non-phospholipid vesicles as carriers for peptides and proteins: Production, characterization and stability studies. International Journal of Pharmaceutics, 2007, 339, 52-60.	5.2	26
18	Quercetin microspheres by solvent evaporation: Preparation, characterization and release behavior. Journal of Applied Polymer Science, 2008, 109, 2994-3001.	2.6	23

#	Article	IF	CITATIONS
19	Floating modular drug delivery systems with buoyancy independent of release mechanisms to sustain amoxicillin and clarithromycin intra-gastric concentrations. Drug Development and Industrial Pharmacy, 2016, 42, 332-339.	2.0	23
20	Nebulized coenzyme Q 10 nanosuspensions: A versatile approach for pulmonary antioxidant therapy. European Journal of Pharmaceutical Sciences, 2018, 113, 159-170.	4.0	23
21	Agglomerated Oral Dosage Forms of Artemisinin/ \hat{l}^2 -Cyclodextrin Spray-Dried Primary Microparticles Showing Increased Dissolution Rate and Bioavailability. AAPS PharmSciTech, 2013, 14, 911-918.	3.3	22
22	Nasal powders of thalidomide for local treatment of nose bleeding in persons affected by hereditary hemorrhagic telangiectasia. International Journal of Pharmaceutics, 2016, 514, 229-237.	5.2	22
23	Anti-inflammatory flurbiprofen nasal powders for nose-to-brain delivery in Alzheimer's disease. Journal of Drug Targeting, 2019, 27, 984-994.	4.4	21
24	Excipient-free pulmonary insulin dry powder: Pharmacokinetic and pharmacodynamics profiles in rats. Journal of Controlled Release, 2020, 323, 412-420.	9.9	21
25	Layered lipid microcapsules for mesalazine delayed-release in children. International Journal of Pharmaceutics, 2011, 421, 293-300.	5.2	20
26	Combinations of colistin solutions and nebulisers for lung infection management in cystic fibrosis patients. International Journal of Pharmaceutics, 2016, 502, 242-248.	5.2	19
27	Therapeutic Paint of Cidofovir/Sucralfate Gel Combination Topically Administered by Spraying for Treatment of orf virus Infections. AAPS Journal, 2009, 11, 242-249.	4.4	18
28	Development and validation of a DESIâ€HRMS/MS method for the fast profiling of esomeprazole and its metabolites in rat plasma: a pharmacokinetic study. Drug Testing and Analysis, 2016, 8, 208-213.	2.6	18
29	Aerosolization Performance of Jet Nebulizers and Biopharmaceutical Aspects. Pharmaceutics, 2019, 11, 406.	4.5	18
30	New Farnesane Sesquiterpenes from Lactarius porninsis. Journal of Natural Products, 1993, 56, 1948-1953.	3.0	14
31	Chlorhexidine Salt-Loaded Polyurethane Orthodontic Chains: In Vitro Release and Antibacterial Activity Studies. AAPS PharmSciTech, 2012, 13, 1446-1450.	3.3	14
32	Pharmacokinetics evaluation of soft agglomerates for prompt delivery of enteric pantoprazole-loaded microparticles. European Journal of Pharmaceutics and Biopharmaceutics, 2010, 74, 275-280.	4.3	13
33	High shear mixing of lactose and salmeterol xinafoate dry powder blends: Biopharmaceutic and aerodynamic performances. Journal of Drug Delivery Science and Technology, 2015, 30, 443-449.	3.0	13
34	Inhalable Microparticles Embedding Calcium Phosphate Nanoparticles for Heart Targeting: The Formulation Experimental Design. Pharmaceutics, 2021, 13, 1825.	4.5	13
35	Polymorphism of rac-5,6-diisobutyryloxy-2-methylamino-1,2,3,4-tetrahydro-naphthalene hydrochloride (CHF 1035). I. Thermal, spectroscopic, and X-ray diffraction properties. Journal of Pharmaceutical Sciences, 2001, 90, 1154-1163.	3.3	12
36	Agglomerates Containing Pantoprazole Microparticles: Modulating the Drug Release. AAPS PharmSciTech, 2009, 10, 335-345.	3.3	12

#	Article	IF	CITATIONS
37	Comparison of breaking tests for the characterization of the interfacial strength of bilayer tablets. International Journal of Pharmaceutics, 2016, 513, 709-716.	5.2	12
38	Esomeprazole immediate release tablets: Gastric mucosa ex vivo permeation, absorption and antisecretory activity in conscious rats. Journal of Controlled Release, 2016, 239, 203-210.	9.9	12
39	Development of solid lipid microparticles by melt-emulsification/spray-drying processes as carriers for pulmonary drug delivery. European Journal of Pharmaceutical Sciences, 2021, 156, 105588.	4.0	12
40	Multi-kinetics and site-specific release of gabapentin and flurbiprofen from oral fixed-dose combination: in vitro release and in vivo food effect. Journal of Controlled Release, 2017, 262, 296-304.	9.9	10
41	Dry powder inhaler of colistimethate sodium for lung infections in cystic fibrosis: optimization of powder construction. Drug Development and Industrial Pharmacy, 2019, 45, 1664-1673.	2.0	8
42	Comparative Assessment of In Vitro and In Silico Methods for Aerodynamic Characterization of Powders for Inhalation. Pharmaceutics, 2021, 13, 1831.	4.5	7
43	Complex product composition generates risks for generic substitution also with dosage forms for intravenous administration. International Journal of Pharmaceutics, 2013, 451, 50-56.	5.2	4
44	Innovative Technologies for Oral Drug Delivery. Current Drug Delivery, 2013, 10, 4-8.	1.6	1